BioCryst Pharmaceuticals (BCRX) said Monday that the Health Services Executive in Ireland has recommended Orladeyo for the routine prevention of recurrent attacks of hereditary angioedema in patients who are at least 12 years old.

The decision follows European Commission marketing authorization of the drug, also called berotralstat, in April 2021.

The orally ingested, once-daily drug is designed to prevent hereditary angioedema attacks by decreasing the activity of plasma kallikrein, the company said.

Price: 8.50, Change: +0.07, Percent Change: +0.83